<DOC>
	<DOC>NCT01776047</DOC>
	<brief_summary>Study Design : randomized, open label, single-dose, 2-way cross-over design Phase : Phase I</brief_summary>
	<brief_title>A Randomized, Open Label, Single Dose, 2-Way Cross-over Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Exforge® and G-0081 in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Amlodipine, Valsartan Drug Combination</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>healthy male volunteers between the ages of 20 to 50 years old within the range of ±20% of IBW(Ideal Body Weight) having neither congenital/chronic diseases nor pathological symptoms/findings as results of medical examination doctor determines to be suitable as subjects within 4 weeks ago before administration Hypersensitivity(or history of hypersensitivity) to amlodipine and valsartan Active Liver Diseases or exceed 1.5 times the normal range of AST, ALT Gastrointestinal diseases or surgeries that affect absorption of drug Excessive drinking(exceed 30g/week) and excessive caffeine(exceed 250mg/day) Smoking over 10 cigarettes per day</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>